Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Weber, Donna M., Chen, Christine, Niesvizky, Ruben, Wang, Michael, Belch, Andrew, Stadtmauer, Edward A., Siegel, David, Borrello, Ivan +8 more·2007·New England Journal of Medicine

DOI 10.1056/nejmoa070596

Cited by (1,000)

Items 601–700 of 1,000

Observations of Second Primary Malignancy in Patients With Multiple Myeloma
Anne Ormerod, Christopher A. Fausel, Rafat Abonour, Patrick J. Kiel · 2011 · Clinical Lymphoma Myeloma & Leukemia
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Paul Gerard Guy Richardson, Jacob P. Laubach, Constantine S. Mitsiades, Robert L Schlossman, Deborah S. Doss, Kathleen Colson, Mary McKenney, Kimberly Noonan, Diane L. Warren, Irene M. Ghobrial et al. · 2010 · PubMed
Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch
Doménico Ribatti, Angelo Vacca · 2016 · Cancer treatment and research
The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma
Andrea Messori, Dario Maratea, Chiara Nozzoli, Alberto Bosi · 2011 · PharmacoEconomics
DFT Study on the Interaction of Lenalidomide Anticancer Drug on the Surface of B12N12 Nanocluster
Shamsa Sharifi, Masoome Sheikhi, Siyamak Shаhаb, Sadegh Kaviani, Rakesh Kumar · 2021 · Letters in Organic Chemistry
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
Maarten R. Seefat, David G. J. Cucchi, Stijn Dirven, Kaz Groen, Sonja Zweegman, Hedwig M. Blommestein · 2021 · Cancers
Treatment trade‐offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies
Brian Leslie Burnette, Angela A. Dispenzieri, Shaji Kunnathu Kumar, Ann M. Harris, Jeff A. Sloan, Jon Charles Tilburt, Robert A. Kyle, S. Vincent Rajkumar · 2013 · Cancer
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment
Meletios Athanasios Dimopoulos, Evangelos Terpos, Hartmut Goldschmidt, Adrián Macías Alegre, Tomer Martin Mark, Rubén Niesvizky · 2012 · Cancer Treatment Reviews
Review of therapy for relapsed/refractory multiple myeloma
José Mariz, Graça Vasconcelos Esteves · 2012 · Current Opinion in Oncology
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis
Rachid Baz, Mehul P. Patel, Elizabeth Finley-Oliver, Daniel J. Lebovic, Mohamad A. Hussein, Kena C. Miller, Margaret Wood, Taimur Sher, Kelvin P. Lee, Asher Alban Chanan-Khan · 2010 · Leukemia & lymphoma/Leukemia and lymphoma
Lenalidomide in multiple myeloma: current role and future directions
Jerome B. Zeldis, Robert Knight, Christian J. Jacques, Alison Tozer, Jean-Pierre Bizzari · 2010 · Expert Opinion on Pharmacotherapy
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma
Heinz Ludwig, Niklas Zojer · 2010 · Nature Reviews Clinical Oncology
Complications of Multiple Myeloma Therapy, Part 2: Risk Reduction and Management of Venous Thromboembolism, Osteonecrosis of the Jaw, Renal Complications, and Anemia
Rubén Niesvizky, Ashraf Z. Badros · 2010 · Journal of the National Comprehensive Cancer Network
The risk of secondary primary malignancies after therapy for multiple myeloma
Nuchanan Areethamsirikul, Donna Ellen Reece · 2015 · Leukemia & lymphoma/Leukemia and lymphoma
Updates on thrombotic events associated with multiple myeloma
Despina Fotiou, Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Magdalini Migkou, Meletios Athanasios Dimopoulos, Evangelos Terpos · 2019 · Expert Review of Hematology
Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide
Sridhar Srinivasan, Charles Alan Schiffer · 2008 · Leukemia Research
Novel treatment regimens for Waldenström’s macroglobulinemia
Ramón García‐Sánz, Enrique M. Ocio · 2010 · Expert Review of Hematology
Multiple myeloma: the disease and its treatment
Meenakshi Gupta, R. N. Pal, Deepika Tikoo · 2013 · International Journal of Basic & Clinical Pharmacology
The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes
Joseph J. Bonkowski, Lee C. Vermeulen, Jill Kolesar · 2009 · Journal of Oncology Pharmacy Practice
New pharmacotherapy options for multiple myeloma
Roberto Mina, Chiara Cerrato, Annalisa Bernardini, Elena Aghemo, Antonio Pierangelo Palumbo · 2015 · Expert Opinion on Pharmacotherapy
Activation of coagulation by a thalidomide-based regimen
Asuka Hoshi, Aya Matsumoto, Jihwa Chung, Yu Isozumi, Takatoshi Koyama · 2011 · Blood Coagulation & Fibrinolysis
Bone marrow vascular niche and the control of angiogenesis in multiple myeloma
Doménico Ribatti · 2014 · Frontiers in bioscience
Population pharmacokinetics of lenalidomide in multiple myeloma patients
Beatriz Guglieri-López, Alejandro Pérez‐Pitarch, Dirk Jan A. R. Moes, Begoña Porta-Oltra, Mónica Climente Martí, Henk‐Jan Guchelaar, Matilde Merino‐Sanjuán · 2016 · Cancer Chemotherapy and Pharmacology
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma
Jack Khouri, Beth M Faiman, Dale Grabowski, Reda Z. Mahfouz, Shahper N. Khan, Wei Wei, Jason Neil Valent, Robert M. Dean, Christy Joy Samaras, Babal Kant Jha et al. · 2020 · Seminars in Hematology
Novel drugs for the treatment of multiple myeloma
J Bladé, María Teresa Cibeira, Laura Rosiñol · 2010 · Haematologica
Lenalidomide and its role in the management of multiple myeloma
Patrizia Falco, Federica Cavallo, Alessandra Larocca, Anna Marina Liberati, Pellegrino Musto, Mario Boccadoro, Antonio Palumbo · 2008 · Expert Review of Anticancer Therapy
Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q
Isaac Park, Tra Mi Phan, Jing Fang · 2021 · Cancers
Immunomodulatory Agents for Multiple Myeloma
Jiří Minařík, Sabina Ševčı́ková · 2022 · Cancers
The emerging role of targeted protein degradation to treat and study cancer
Maximillian Hugo Brodermann, Elizabeth K Henderson, Rob S. Sellar · 2024 · The Journal of Pathology
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
Jeremy Todd Larsen, Shaji Kunnathu Kumar · 2015 · Rare Cancers and Therapy
Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer’s perspective
Felicitas Kühne, Thomas Mittendorf, Ulrich Germing, Hans Tesch, R Weinberg, Ulrich Grabenhorst, Andreas Mohr, Rainer Lipp, Johann Mathias von der Schulenburg · 2010 · Annals of Hematology
Novel immunomodulatory compounds in multiple myeloma
Neeraj Saini, Anuj Kumar Mahindra · 2012 · Expert Opinion on Investigational Drugs
Lenalidomide treatment for patients with multiple myeloma: Diagnosis and management of most frequent adverse events
Ernesto Pérez Persona, Mercedes Gironella, Pedro José García Sánchez, Ana Pilar González · 2011 · Advances in Therapy
Immunomodulating antibodies and drugs for the treatment of hematological malignancies
Roch Houot, Holbrook E K Kohrt, Matthew Jordan Goldstein, Ronald Levy · 2011 · Cancer and Metastasis Reviews
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open‐label, phase 1/2 study
Torben Plesner, Hendrik‐Tobias Arkenau, Francesca Gay, Monique C. Minnema, Mario Boccadoro, Philippe Moreau, Jamie D. Cavenagh, Aurore Perrot, Jacob P. Laubach, Jakub Krejcik et al. · 2019 · British Journal of Haematology
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development
Ahmad Iftikhar, Hamza Hassan, Nimra Iftikhar, Adeela Mushtaq, Atif Sohail, Nathaniel Rosko, Rajshekhar Chakraborty, Faryal Razzaq, Sonia Sandeep, Jason Neil Valent et al. · 2019 · Antibodies
Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances
Massimiliano Camilli, Giulia La Vecchia, Rosa Lillo, Giulia Iannaccone, Priscilla Lamendola, Rocco Antonio Montone, Stefan Hohaus, Nadia Aspromonte, Massimo Massetti, Gaetano Antonio Lanza et al. · 2021 · Expert Review of Hematology
Virus Infection, Inflammation and Prevention of Cancer
Norman Woller, Florian Kühnel · 2013 · Recent results in cancer research/Recent Results in Cancer Research
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib‐containing regimens
Giulia Benevolo, Alessandra Larocca, Massimo Gentile, Patrizia Pregno, Francesca Gay, Barbara Botto, Chiara Frairia, Andrea Evangelista, Fortunato Morabito, Mario Boccadoro et al. · 2010 · Cancer
Lenalidomide‐associated pneumonitis in patients with plasma cell dyscrasias
Flora Zagouri, Μαρία Ρούσσου, Efstathios Kastritis, Andreas P. Koureas, Eleni Tsokou, Magdalini Migkou, Maria Gavriatopoulou, Nikitas Nikitas, Maria Aslani Gkotzamanidou, Evangelos Terpos et al. · 2011 · American Journal of Hematology
Benefits of Early Roflumilast Treatment After Hospital or Emergency Department Discharge for a COPD Exacerbation.
Qing Lee, Michelle Mocarski, Shawn X. Sun · 2016 · PubMed Central
Novel lenalidomide-based combinations for treatment of multiple myeloma
Mauro Cives, Valeria De Simone, Oronzo Brunetti, Vito Longo, Franco Silvestris · 2012 · Critical Reviews in Oncology/Hematology
Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma
K. Jack Ishak, J. Jaime, Mark Trehane Drayson, Meletios Athanasios Dimopoulos, Donna Weber, Bradley M. Augustson, J. Anthony Child, Robert Knight, Gulnaz Iqbal, Janet Dunn et al. · 2011 · Value in Health
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against
Paul Gerard Guy Richardson, Sarah A. Holstein, Robert L Schlossman, Kenneth Carl Anderson, Michel Attal, Philip L. McCarthy · 2017 · Expert Opinion on Pharmacotherapy
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal
Xavier Armoiry, Martin J Connock, Alexander Tsertsvadze, Ewen Cummins, G. J. Meléndez‐Torres, Pam Royle, Aileen Clarke · 2018 · PharmacoEconomics
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France
Huamao Mark Lin, Keith L. Davis, James A. Kaye, Katarina Luptakova, Saurabh P. Nagar, Mohamad Mohty · 2019 · Advances in Hematology
Risk assessment of venous thromboembolism in hematological cancer patients: a review
Thomas S. Y. Chan, Yu‐Yan Hwang, Eric Tse · 2020 · Expert Review of Hematology
A steroid‐independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
Taimur Sher, Sikander Ailawadhi, Kena C. Miller, Debbie Manfredi, Margaret Wood, Wei Tan, Gregory E. Wilding, Myron Stefan Czuczman, Francisco J. Hernandez‐Ilizaliturri, Fredrick Hong et al. · 2011 · British Journal of Haematology
Lenalidomide: a synthetic compound with an evolving role in cancer management
Vassiliki Saloura, Petros D. Grivas · 2010 · Hematology
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update
Martha Q. Lacy, Ayalew Tefferi · 2011 · Leukemia & lymphoma/Leukemia and lymphoma
Treatment of relapsed and refractory myeloma
Donna Ellen Reece, Heather A. Leitch, Harold L. Atkins, Michael Voralia, Leah A. Canning, Richard LeBlanc, Andrew R. Belch, Darrell J. White, Michael J. Kovacs · 2008 · Leukemia & lymphoma/Leukemia and lymphoma
Myélome multiple : diagnostic clinique et perspective de traitement. Recommandations de l’International Myeloma Working Group (IMWG)
Salomon Manier, Xavier P Leleu · 2011 · Immuno-analyse & Biologie Spécialisée
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea—experience from 110 patients
Korean Multiple Myeloma Working Party (KMMWP), Kihyun Kım, Seok Jin Kim, Verena Voelter, Cheolwon Suh, Sung‐Soo Yoon, Je‐Jung Lee, Jae‐Yong Kwak, Hun Mo Ryoo, Yang Soo Kim et al. · 2013 · Annals of Hematology
EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage
Isabel Püntmann, Norbert Schmacke, Arne Melander, Gunnar Lindberg, Bernd Mühlbauer · 2010 · BMC Clinical Pharmacology
Effects of induction with novel agentsversusconventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
Don M. Benson, Kathryn Panzner, Mehdi Hamadani, Craig C. Hofmeister, Courtney E. Bakan, Megan Smith, Pat Elder, David Krugh, Lynn C. O’Donnell, Steven Michael Devine · 2009 · Leukemia & lymphoma/Leukemia and lymphoma
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Irene M. Ghobrial, A. Keith Stewart · 2009 · Hematology
Asymptomatic Multiple Myeloma Presenting as a Nodular Hepatic Lesion: A Case Report and Review of the Literature.
Hans Huang, Fateh Bazerbachi, Hector A. Mesa, Pankaj Gupta · 2015 · PubMed
Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
Kenshi Suzuki, Atsushi Shinagawa, Toshiki Uchida, Masafumi Taniwaki, Hirokazu Hirata, Kenichi Ishizawa, Kosei Matsue, Yoshiaki Ogawa, Takayuki Shimizu, Maki Otsuka et al. · 2016 · Cancer Science
Patient with Refractory Multiple Myeloma Developing Eosinophilia after Lenalidomide Treatment and Lung Cancer 9 Months Later: Case Report and Review of the Literature
Yasunobu Sekiguchi, Asami Shimada, Hidenori Imai, Mutsumi Wakabayashi, Keiji Sugimoto, Noriko Nakamura, Tomohiro Sawada, Norio Komatsu, Masaaki Noguchi · 2014 · Indian Journal of Hematology and Blood Transfusion
Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
Wendong Chen, Yicheng Yang, Yi Chen, Fen Du, Huan Zhan · 2016 · ClinicoEconomics and Outcomes Research
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma
Francesca Donato, Francesca Gay, Sara Bringhen, Rossella Troia, Antonio Pierangelo Palumbo · 2014 · Expert Opinion on Biological Therapy
Precision preclinical modeling to advance cancer treatment
David H. Gutmann, Jesse S. Boehm, Elinor K. Karlsson, Eric Padron, Mukund Seshadri, DEEANN E. WALLIS, Joshua C. Snyder · 2024 · JNCI Journal of the National Cancer Institute
Part I: The Role of Maintenance Therapy in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Philip L. McCarthy · 2013 · Journal of the National Comprehensive Cancer Network
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide
Tzu‐Fei Wang, Rohan Ahluwalia, Mark Aaron Fiala, Kathryn M. Trinkaus, Doug Cox, Matthew Jaenicke, Caitlin C. Moliske, Kenneth Robert Carson, Tanya Marya Wildes, Michael H. Tomasson et al. · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
Dao-Bin Zhou, Li Yu, Xin Du, Jie Jin, Zhen Cai, Fangping Chen, Xiaoyan Ke, Xiao Li, Depei Wu, Fan‐Yi Meng et al. · 2015 · International Journal of Hematology
Lenalidomide: an update on evidence from clinical trials
Meletios Athanasios Dimopoulos, Evangelos Terpos · 2010 · Blood Reviews
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
Katja Christina Weisel · 2016 · OncoTargets and Therapy
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma
James R. Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi J. McIntyre, Roger M. Lyons, Wael A. Harb, Hesham Mohamed, Ali Nourbakhsh, Robert M. Rifkin · 2017 · American Journal of Hematology
Maintenance and continuous therapy for multiple myeloma
Paul Gerard Guy Richardson, Jacob P. Laubach, Sara Gandolfi, Thierry T.F. Facon, Katja Christina Weisel, Peter O’Gorman · 2018 · Expert Review of Anticancer Therapy
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma
Evangelos Terpos, Eirini Katodritou, Argiris S. Symeonidis, Flora Zagouri, Antonis Gerofotis, Georgia Christopoulou, Maria Gavriatopoulou, Dimitrios Christoulas, Ioannis Ntanasis‐Stathopoulos, Alexandra Kourakli et al. · 2019 · International Journal of Cancer
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma
Shannon F. Cope, Kabirraaj Toor, Evan Popoff, Rafaël Fonseca, Ola Landgren, María‐Victoria Mateos, Katja Christina Weisel, Jeroen Paul Jansen · 2020 · Value in Health
Future Novel Single Agent and Combination Therapies
Diana D. Cirstea, Sonia Vallet, Noopur S Raje · 2009 · The Cancer Journal
Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy.
Sofia Ghani, Omar Al Ustwani, Bilal Khalid, Paul N. Bogner, Marcelle A. Grassi, Jennifer Powell, Seema Ali Bhat · 2013 · PubMed
Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation
Paul L. McCormack · 2015 · Drugs & Aging
Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee
Noopur S Raje, Beth M Faiman, Robert Donald Harvey, Sandra E Kurtin, Sagar Lonial, Shaji Kunnathu Kumar, Adam D. Cohen, Miguel Á. Conde, Sergio Giralt, Marie Sabo Recine et al. · 2014 · Clinical Lymphoma Myeloma & Leukemia
The use of Novel Agents in Multiple Myeloma Patients with Hepatic Impairment
Lindsay Stansfield, Wilson I. Gonsalves, Francis K. Buadi · 2015 · Future Oncology
External phenome analysis enables a rational federated query strategy to detect changing rates of treatment-related complications associated with multiple myeloma
Jeremy Lyle Warner, Gil Alterovitz, Kelly Bodio, Robin Joyce · 2013 · Journal of the American Medical Informatics Association
Next-Generation Therapies for Multiple Myeloma
Erin W. Meermeier, Peter Leif Bergsagel, Marta Chesi · 2024 · Annual Review of Cancer Biology
Advances in treatment for relapses and refractory multiple myeloma
Tiffany Ann Richards, Donna Weber · 2010 · Medical Oncology
Management of Mantle Cell Lymphoma: Key Challenges and Next Steps
Michael E. Williams, Martin H. Dreyling, Jane N. Winter, Sabeeha Muneer, John Paul Leonard · 2010 · Clinical Lymphoma Myeloma & Leukemia
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma
Cyrille Touzeau, Nicolas Blin, Aline Clavert, Virginie Roland, Marion Loirat, Benoît Tessoulin, Steven Le Gouill, Lucie Planche, Martine Pennetier, Beatrice Mahé et al. · 2012 · Leukemia & lymphoma/Leukemia and lymphoma
Myeloma Kidney: Improving Clinical Outcomes?
Richard Haynes, Nelson Leung, Robert A. Kyle, Christopher G. Winearls · 2012 · Advances in Chronic Kidney Disease
New Immunomodulatory Drugs in Myeloma
Martha Q. Lacy · 2011 · Current Hematologic Malignancy Reports
Genomic stratification of multiple myeloma treated with novel agents
Allan Jiang, Donna Ellen Reece, Hong Chang · 2011 · Leukemia & lymphoma/Leukemia and lymphoma
Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma
Andrew T. Hutchinson, Darren R. Jones, Robert L. Raison · 2015 · Molecular Immunology
Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
Lucia Chen, Sarah Gooding · 2022 · Frontiers in Oncology
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment
Manola Zago, Katharina Oehrlein, Corinna Rendl, Corinna Hahn‐Ast, Lothar Kanz, Katja Christina Weisel · 2014 · Annals of Hematology
Oncology: Treatment of Multiple Myeloma in the Targeted Therapy Era
Ayman A Saad, Manish R. Sharma, Gerald M. Higa · 2009 · Annals of Pharmacotherapy
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature
Patrizia Mondello, Vincenzo V. Pitini, Carmela Arrigo, Stefania Mondello, Michael Mian, Giuseppe Altavilla · 2014 · SpringerPlus
Lenalidomide (Revlimid): A Thalidomide Analogue in Combination With Dexamethasone For the Treatment of All Patients With Multiple Myeloma.
Martin Paspe Cruz · 2016 · PubMed Central
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma
Satish Stephen Maharaj, Simone Chang, Karan Seegobin, Ivan Serrano-Santiago, Lara Zuberi · 2017 · Expert Review of Anticancer Therapy
Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone
Korean Multiple Myeloma 151 Investigators, Junghoon Shin, Je‐Jung Lee, Kihyun Kım, Chang‐Ki Min, Jeong‐Ok Lee, Cheolwon Suh, Jin Seok Kim, Yoo Jin Lee, Sung‐Soo Yoon et al. · 2018 · International Journal of Hematology
The Potential of Immunomodulatory Drugs in the Treatment of Solid Tumors
Angus George Dalgleish, Christine Galustian · 2010 · Future Oncology
How best to use new therapies in multiple myeloma
David Dingli, S. Vincent Rajkumar · 2010 · Blood Reviews
Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma
Kimberly Ann Noonan, Kathleen Colson · 2017 · Seminars in Oncology Nursing
Major Advances in the Treatment of Cancer What does a Non-Oncologist need to know?
Ikram Ali Burney, Mansour S. Al-Moundhri · 2008 · Sultan Qaboos University medical journal
Incorporating Monoclonal Antibodies Into the Therapy of Multiple Myeloma
Joan Bladé, Carlos Fernández de Larrea, Laura Rosiñol · 2012 · Journal of Clinical Oncology
The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib
Paul Gerard Guy Richardson, Jacob P. Laubach, Robert L Schlossman, Irene M. Ghobrial, Katherine Redman, Mary McKenney, Diane L. Warren, Kimberly Noonan, Laura E. Lunde, Deborah S. Doss et al. · 2012 · European Journal Of Haematology
Targeted molecular therapy in peripheral T-cell lymphomas
Fernando Roncolato, Anna Gazzola, Pier Luigi Zinzani, Stefano Aldo Pileri, Pier Paolo Piccaluga, for the European T-cell Lymphoma Study Group · 2011 · Expert Review of Hematology
Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation
Nina D. Shah, Sagar Lonial · 2010 · Hematology